CeriBell, Inc.
NASDAQ:CBLLMedical - Devices
+$0.25 today
- Market cap
- $995.34M
- Beta
- 0.84
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$1.60
Volume 0.41M
Average 0.29M
CBLL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
CeriBell, Inc.NASDAQ: CBLL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$19.06M, compared with -$11.97M a year earlier. Trailing-twelve-month EBITDA was -$57.27M.
Context
- EBITDA amounted to 56.3% of revenue in FY2025, down 0.7 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$69.95M (-39.4%) for the fiscal year ending Dec 2026, a slowdown from the -34.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.06M-49.2% QoQ
- Last fiscal yearDec 2025
- -$50.18M-34.5% YoY
- LTMMar 2026
- -$57.27M-38.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -59.3% | -35.9% | +23.3 pp |
| 1 year | -34.5% | -39.4% | -4.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (50.18M) USD
- Year-over-year change
- -34.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (50.18M) | -34.5% |
| FY2024 | 2024-12-31 | (37.32M) | -40.8% |
| FY2023 | 2023-12-31 | (26.51M) | +24.4% |
| FY2022 | 2022-12-31 | (35.06M) | — |
EBITDA vs competitors
How CBLL compares with its peers on the latest reported figures
- CBLL's LTM Mar 2026 EBITDA of -$57.27M is the lowest of the 7 companies compared; the peer median is -$13.56M.
- Its year-over-year change of -38.6% is the lowest of 7, against a peer median of +18.6%.
- EBITDA amounts to 60.2% of revenue for CBLL, versus a peer median of 19.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $211.36M | +363.4% | — | 14.0% | |
| LTM Mar 2026 | $12.57M | +90.6% | — | 22.4% | |
| LTM Mar 2026 | -$13.27M | -20.5% | — | 38.0% | |
| LTM Mar 2026 | -$13.84M | +3.2% | — | 13.9% | |
| LTM Mar 2026 | -$25.7M | +34.0% | — | 17.0% | |
| LTM Mar 2026 | -$45.97M | -0.0% | — | 77.8% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -$57.27M | -38.6% | — | 60.2% |
| Peer median (excluding CBLL) | -$13.56M | +18.6% | — | 19.7% | |
Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 25.92M | 45.23M | 65.44M | 89.06M |
| Cost of Revenue | 4.43M | 7.06M | 8.69M | 10.79M |
| Gross Profit | 21.49M | 38.16M | 56.75M | 78.27M |
| Gross Margin | 82.9% | 84.4% | 86.7% | 87.9% |
| Research & Development | 7.24M | 9M | 13.56M | 19.14M |
| Selling, General & Admin | 50.27M | 59.21M | 82.9M | 117.53M |
| Operating Expenses | 57.51M | 68.2M | 96.46M | 136.68M |
| Depreciation & Amortization | 497K | 847K | 1.14M | 1.34M |
| EBITDA | (35.06M) | (26.51M) | (37.32M) | (50.18M) |
| EBITDA Margin | -135.3% | -58.6% | -57.0% | -56.3% |
| Operating Income | (36.02M) | (30.04M) | (39.71M) | (58.4M) |
| Operating Margin | -139.0% | -66.4% | -60.7% | -65.6% |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 1.6M | 2.1M | 1.99M | 1.89M |
| Other Income / Expenses | (1.14M) | 588K | (746K) | 4.99M |
| Income Before Tax | (37.16M) | (29.45M) | (40.46M) | (53.41M) |
| Pre-Tax Margin | -143.4% | -65.1% | -61.8% | -60.0% |
| Income Tax Expense | 2K | 11K | 0 | 0 |
| Net Income | (37.16M) | (29.46M) | (40.46M) | (53.41M) |
| Net Margin | -143.4% | -65.1% | -61.8% | -60.0% |
| EPS (Basic) | (1.59) | (1.26) | (3.39) | (1.46) |
| EPS (Diluted) | (1.59) | (1.26) | (3.39) | (1.46) |
| Weighted Avg Shares | 23.32M | 23.32M | 11.95M | 36.54M |
| Weighted Avg Shares (Diluted) | 23.32M | 23.32M | 11.95M | 36.54M |
CeriBell, Inc.
NASDAQ:CBLL
Intrinsic Alpha fair value
Locked
Current Price
$25.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.